Nothing Special   »   [go: up one dir, main page]

DE60209907D1 - Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen - Google Patents

Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen

Info

Publication number
DE60209907D1
DE60209907D1 DE60209907T DE60209907T DE60209907D1 DE 60209907 D1 DE60209907 D1 DE 60209907D1 DE 60209907 T DE60209907 T DE 60209907T DE 60209907 T DE60209907 T DE 60209907T DE 60209907 D1 DE60209907 D1 DE 60209907D1
Authority
DE
Germany
Prior art keywords
progestogen
formula
estrogenic component
progestin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60209907T
Other languages
English (en)
Other versions
DE60209907T2 (de
Inventor
Johannes Bunschoten
Bennink Jan Coelingh
Franz Holinka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pantarhei Bioscience BV
Original Assignee
Pantarhei Bioscience BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience BV filed Critical Pantarhei Bioscience BV
Publication of DE60209907D1 publication Critical patent/DE60209907D1/de
Application granted granted Critical
Publication of DE60209907T2 publication Critical patent/DE60209907T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60209907T 2001-05-18 2002-05-17 Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen Expired - Lifetime DE60209907T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01201896 2001-05-18
EP01201896A EP1260225A1 (de) 2001-05-18 2001-05-18 Pharmazeutische Zusammensetzung für die Hormonersatztherapie
PCT/NL2002/000316 WO2002094275A1 (en) 2001-05-18 2002-05-17 Use of estrogen compounds to increase libido in women

Publications (2)

Publication Number Publication Date
DE60209907D1 true DE60209907D1 (de) 2006-05-11
DE60209907T2 DE60209907T2 (de) 2006-08-17

Family

ID=8180347

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60209907T Expired - Lifetime DE60209907T2 (de) 2001-05-18 2002-05-17 Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen

Country Status (9)

Country Link
US (1) US7723320B2 (de)
EP (3) EP1260225A1 (de)
AT (1) ATE320259T1 (de)
CA (1) CA2447175C (de)
DE (1) DE60209907T2 (de)
DK (1) DK1390039T3 (de)
ES (1) ES2260441T3 (de)
PT (1) PT1390039E (de)
WO (1) WO2002094275A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
DK1390040T3 (da) 2001-05-18 2007-04-23 Pantarhei Bioscience Bv Farmaceutisk præparat til anvendelse i hormonerstatningsterapi
CA2448273C (en) 2001-05-23 2010-06-29 Christian Franz Holinka Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US7732430B2 (en) 2001-05-23 2010-06-08 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
DK1446128T3 (da) 2001-11-15 2007-04-02 Pantarhei Bioscience Bv Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
DE60308679T2 (de) 2002-06-11 2007-08-16 Pantarhei Bioscience B.V. Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung
CA2489270C (en) 2002-06-11 2012-08-07 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
WO2004006936A1 (en) 2002-07-12 2004-01-22 Pantarhei Biosciences B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
ES2298570T3 (es) 2002-10-23 2008-05-16 Pantarhei Bioscience B.V. Composiciones farmaceuticas que comprenden derivados de estetrol para el uso en la terapia del cancer.
CA2505190C (en) 2002-11-08 2012-07-10 Pantarhei Bioscience B.V. Synthesis of estetrol via estrone derived steroids
US7371741B2 (en) * 2003-05-28 2008-05-13 Entremed, Inc. Estradiol derivatives and pharmaceutical compositions using same
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
PL1748756T3 (pl) * 2004-03-10 2009-10-30 Bayer Schering Pharma Ag Kompozycje zawierające molekularnie zdyspergowany drospirenon
EP1756139A4 (de) * 2004-03-12 2009-07-29 Entremed Inc Antiangiogene mittel
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
CA2566699C (en) 2004-05-11 2016-02-16 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
CA2587448A1 (en) * 2004-11-29 2006-06-01 Entremed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US8399440B2 (en) * 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
EP1925307A1 (de) * 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
EP2114412B1 (de) 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
ES2376793T3 (es) 2007-07-19 2012-03-16 Pantarhei Bioscience B.V. Tratamiento o prevención de trastornos hipertensivos del embarazo o retraso del crecimiento fetal
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
EP4079308A1 (de) 2008-12-23 2022-10-26 Quest Diagnostics Investments Incorporated Massenspektrometrischer test für östrogenverbindungen
HUE029252T2 (en) 2011-06-01 2017-02-28 Estetra Sprl Process for the preparation of intermediates of estetrol
SG195121A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
EP2383279A1 (de) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Herstellungsverfahren für Esterol
WO2013034780A2 (en) 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
ES2624667T3 (es) 2013-09-18 2017-07-17 Crystal Pharma, S.A.U. Procedimiento para la preparación de estetrol
CN103636555A (zh) * 2013-11-11 2014-03-19 徐又佳 小鼠去势高铁骨质疏松模型构建方法
HUE035848T2 (en) 2013-12-12 2018-05-28 Donesta Bioscience B V Solid dispensing unit containing an estetrol compound in the mouth
JP6866561B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
PE20180398A1 (es) 2015-06-18 2018-02-28 Mithra Pharmaceuticals S A Unidad de dosificacion orodispersable que contiene un componente estetrol
US10888518B2 (en) 2015-06-18 2021-01-12 Estetra Sprl Orodispersible tablet containing estetrol
SI3310333T1 (sl) 2015-06-18 2020-08-31 Estetra Sprl Orodisperzibilna enota odmerka, ki vsebuje komponento estetrola
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2336433A1 (de) * 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) * 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) * 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
US5063507A (en) * 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) * 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) * 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases

Also Published As

Publication number Publication date
EP1390039A1 (de) 2004-02-25
PT1390039E (pt) 2006-07-31
EP1390039B1 (de) 2006-03-15
CA2447175A1 (en) 2002-11-28
EP1700602A1 (de) 2006-09-13
US20040186086A1 (en) 2004-09-23
WO2002094275A8 (en) 2003-02-13
DK1390039T3 (da) 2006-07-10
ATE320259T1 (de) 2006-04-15
CA2447175C (en) 2010-02-16
DE60209907T2 (de) 2006-08-17
ES2260441T3 (es) 2006-11-01
US7723320B2 (en) 2010-05-25
EP1260225A1 (de) 2002-11-27
WO2002094275A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
DE60209907D1 (de) Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen
ATE350041T1 (de) Pharmaceutishe zusammensetzung für die hormonersatztherapie
ATE347365T1 (de) Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
RU2218922C2 (ru) Соединения, имеющие в своей структуре фрагмент производного глюкуроновой кислоты и фрагмент производного глюкозамина, способы получения этих соединений и применение этих соединений
ATE268183T1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
KR950010890A (ko) 폐경기 증후군의 치료방법
MY130668A (en) Isothiazole derivatives useful as anticancer agents
AR034858A1 (es) Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
TW200642685A (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
NZ504986A (en) Erythromycin and azalide derivatives and pharmaceutical compositions thereof, useful as antibacterial agents and antoprotozoa agents
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
AR019669A1 (es) Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen.
YU2703A (sh) Bistar vodeni anestetski preparat
SI1511496T1 (sl) Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
BR9912581A (pt) Processos para tratar ou prevenir um distúrbio causado por disfunção da motilidade gastrointestinal em um humano e para elicitar um efeito procinético em um humano, e, composição farmacêutica
IL105468A0 (en) Pharmaceutical compositions for rectal administration
BR9808249A (pt) Composição farmacêutica, processos para tratar câncer em um mamìfero e para a manufatura de um medicamento para o tratamento de câncer em um mamìfero, e, uso de um composto
BRPI0412118A (pt) métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
KR950701928A (ko) 비정상적인 칼슘 및 인산염 대사를 치료하기 위한 티오-치환된 환상 포스포네이트 화합물(thio-substituted cyclic phosphonate compounds, for treating abnormal calcium and phosphate metabolism)
BR0014447A (pt) Derivados de piperidina como inibidores da reabsorção
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления

Legal Events

Date Code Title Description
8364 No opposition during term of opposition